Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the guillain-barre syndrome market size evolved in recent years?

The market size for Guillain-Barre syndrome has experienced noticeable growth in the last few years. Its size is projected to increase from $0.60 billion in 2024 to $0.64 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The growth experienced in the historical period is associated with an increased need for GBS treatment, a surge in viral infections, expanding worldwide vaccination efforts, an enhanced understanding of autoimmune mechanisms, and a heightened awareness and diagnosis.

What are the predictions for the guillain-barre syndrome market size in the coming years?

The market size of Guillain-Barre Syndrome is projected to experience robust expansion in the forthcoming years, escalating to $0.79 billion by 2029, with a 5.6% Compound Annual Growth Rate (CAGR). This growth for the forecasted period is credited to the escalating occurrence of Guillain-Barre Syndrome, the increasing impact of climate change, the rising application of immunotherapies and drugs, improved diagnostic abilities, and an increase in the incidence of multifocal motor neuropathy. The forecasted period will be characterized by significant trends such as the advancement in diagnostic methods, the introduction of immunoglobulin therapies, the refinement of plasmapheresis procedures, exploration into gene therapy, increased attention to early intervention. Additionally, innovative biomarkers for prognosis and a broadening of clinical trials for inventive treatments are also expected.

Get your guillain-barre syndrome market report here!

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

What key factors are fueling the growth of the guillain-barre syndrome market?

The escalation in the prevalence of immunological diseases is anticipated to spur the growth of the guillain-barre syndrome market in the future. These are conditions where the immune system behaves excessively, insufficiently, or incorrectly, resulting in disorders such as autoimmune diseases, allergies, or immune deficiencies. The rise in these diseases is attributed to factors like environmental shifts, lifestyle alterations, more accurate diagnosis, and genetic predisposition. Immunological diseases can induce guillain-barré syndrome by sparking an autoimmune response, where the body’s immune system mistakenly harms the peripheral nerves, causing inflammation and nerve damage. For example, a report published by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government entity, revealed in July 2024 that by the conclusion of 2022, approximately 39.5 million individuals globally were living with HIV, with 1.3 million new infections and 630,000 AIDS-related fatalities reported within that year. In 2023, the amount of people living with HIV worldwide climbed to around 39.9 million. Consequently, the escalating risk of immunological diseases is fuelling the guillain-barre syndrome market.

How is the global guillain-barre syndrome market divided into key segments?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By Route Of Administration: Parenteral, Oral

4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP

3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp

Who are the key firms paving the way for growth in the guillain-barre syndrome market?

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, Thermo Fisher Scientific Inc., AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., Annexon Inc., Immunovant Inc., CSL Behring LLC, Hansa Biopharma AB, NeuLine Health Inc., Ridge Diagnostics Inc., Deymed Diagnostic LLC, VYVGART Hytrulo.

What emerging trends are influencing the growth of the guillain-barre syndrome market?

Leading firms in the guillain-barre syndrome market are focusing on the development of innovative drugs, such as monoclonal antibodies, to improve the effectiveness of treatments, fulfill unaddressed clinical demands, and broaden their market footprint. Monoclonal antibodies are proteins engineered in a laboratory to target specific antigens, which in turn, assist in manipulating immune reactions and enhancing therapeutic results. For example, in October 2023, Annexon Inc., an American biopharmaceutical firm, earned orphan drug status from the European Medicines Agency (EMA) for its drug ANX005 for treating guillain-barre syndrome (GBS). This drug, a monoclonal antibody that targets C1q, showed early improvements in muscle strength and a decreased necessity for ventilation compared to IVIg, making it a substantial progress in therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21198

What regions are contributing significantly to the growth of the guillain-barre syndrome market?

North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Protein Expression Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-expression-global-market-report

Protein Purification and Isolation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-purification-and-isolation-global-market-report

Global Spinal Surgery Devices And Equipment Global Market Report 2025

https://thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: